Table 2.

Patients with peanut allergy undergoing double-blind placebo-controlled food challenge to peanut.

No	Sex	Age	Cumulative reaction dose(mg PN protein)	Muellergrade	Sampling time†	Emergency treatment
1	M	31	1333	2	PreFC, at reaction, 2h post	Epi at reaction aH1 and HC post reaction
2	M	15	143	3	Pre FC, at reaction	Epi post sampling
3	F	13	4443	3	PreFC, at reaction, 4h post	Epi, aH1, β2-agonist post reaction
4	M	15	1443	3	PreFC, at reaction, 4h post	aH1 at reaction Epi post reaction
5	F	13	1443	2	PreFC, at reaction, at anaphylaxis, 4h post	Epi at 1h post (time of anaphylaxis), aH1 after sampling at 1h
6	M	9	13	3	PreFC, at reaction, 4h post	aH1, Epi after sampling at time of reaction
7	M	9	143	3	PreFC, at reaction, 40min post	Epi, β2-agonist post reaction
8	M	14	443	3	PreFC, at reaction, 4h post	Epi, aH1, β2-agonist, iv fluids post reaction
9	M	22	133	2	PreFC, at reaction, 2h post	aH1, HC post reaction
10	M	27	63	2	PreFC, at reaction, 2h post	aH1, HC post reaction
11	F	13	143	3	Pre FC, at reaction	aH, Epi, HC, β2-agonist after sampling

aH1, H1-antihistamine; Epi, epinephrine; HC, hydrocortisone; iv, intravenous; PN, peanut. †Whole blood samples were collected into PAXgene blood tubes from a venous cannula sited prior to challenge (FC), at time of reaction, and then at the stated timepoint afterwards.